enCore Energy (CVE:EU – Get Free Report) had its price target hoisted by equities researchers at Canaccord Genuity Group from C$8.00 to C$8.50 in a report released on Tuesday, BayStreet.CA reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective would indicate a potential upside of 46.05% from the company’s previous close.
EU has been the topic of several other reports. Ventum Cap Mkts upgraded enCore Energy to a “strong-buy” rating in a research note on Monday, July 8th. Ventum Financial set a C$7.00 price objective on shares of enCore Energy and gave the company a “buy” rating in a report on Thursday, August 22nd.
Read Our Latest Analysis on EU
enCore Energy Stock Up 3.6 %
enCore Energy (CVE:EU – Get Free Report) last announced its earnings results on Wednesday, August 14th. The company reported C($0.07) earnings per share for the quarter. The business had revenue of C$7.28 million during the quarter. enCore Energy had a negative return on equity of 6.92% and a negative net margin of 58.43%.
Insiders Place Their Bets
In other news, Director William Morris Sheriff sold 10,000 shares of the stock in a transaction on Monday, August 26th. The shares were sold at an average price of C$3.80, for a total value of C$38,000.00. 2.12% of the stock is currently owned by company insiders.
enCore Energy Company Profile
enCore Energy Corp. engages in the acquisition, exploration, and development of uranium resource properties in the United States. It holds a 100% interest in the Crownpoint and Hosta Butte uranium project that covers 3,020 acres located in the Grants Uranium Belt, New Mexico. The company also has interests in the Marquez-Juan Tafoya property, which consists of 14,582 acres located in McKinley and Sandoval counties of New Mexico; and the Nose Rock project that covers 42 owned unpatented lode mining claims comprising approximately 800 acres located in McKinley County, New Mexico.
Featured Articles
- Five stocks we like better than enCore Energy
- The 3 Best Retail Stocks to Shop for in August
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Retail Stocks Investing, Explained
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for enCore Energy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enCore Energy and related companies with MarketBeat.com's FREE daily email newsletter.